Xeris Biopharma Holdings (XERS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Xeris Biopharma Holdings (XERS) is Neutral.

The composite score behind that read is -0.15, weighing +0.10 of bullish evidence against -0.22 bearish.

Xeris Biopharma Holdings last closed at $9.08, -1.84% on the session.

Against the IVW growth benchmark the position is -2.81% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

4 graded predictions for XERS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Xeris Biopharma Holdings in the 2nd percentile on return on equity, where 100 is best.

Xeris Biopharma Holdings is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.69B.

StockMap tracks Xeris Biopharma Holdings as the 32nd largest of the 89 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 44 Neutral, 32 Moderate Underperform, 9 Strong Underperform and 4 Moderate Outperform.

On that composite Xeris Biopharma Holdings ranks 45th of 89 in the group, against a group median of -0.15.